Multiple Sclerosis - Pipeline Review, H1 2016 - Global Markets Direct - Market Research

Multiple Sclerosis - Pipeline Review, H1 2016

Multiple Sclerosis - Pipeline Review, H1 2016 - Global Markets Direct - Market Research
Multiple Sclerosis - Pipeline Review, H1 2016
Published Jun 15, 2016
903 pages — Published Jun 15, 2016
Price US$ 2,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Multiple Sclerosis - Pipeline Review, H1 2016, provides an overview of the Multiple Sclerosis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Multiple Sclerosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Multiple Sclerosis and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Multiple Sclerosis
- The report reviews pipeline therapeutics for Multiple Sclerosis by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Multiple Sclerosis therapeutics and enlists all their major and minor projects
- The report assesses Multiple Sclerosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Multiple Sclerosis

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Multiple Sclerosis
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Multiple Sclerosis pipeline depth and focus of In

  
Source:
Document ID
GMDHC7962IDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents242
  List of Tables376
  List of Figures431
Introduction441
  Global Markets Direct Report Coverage441
Multiple Sclerosis Overview451
Therapeutics Development462
  Pipeline Products for Multiple Sclerosis Overview461
  Pipeline Products for Multiple Sclerosis Comparative Analysis471
Multiple Sclerosis Therapeutics under Development by Companies4816
Multiple Sclerosis Therapeutics under Investigation by Universities/Institutes642
Multiple Sclerosis Pipeline Products Glance664
  Late Stage Products661
  Clinical Stage Products671
  Early Stage Products681
  Unknown Stage Products691
Multiple Sclerosis Products under Development by Companies7020
Multiple Sclerosis Products under Investigation by Universities/Institutes903
Multiple Sclerosis Companies Involved in Therapeutics Development93178
  4D Pharma Plc931
  4SC AG941
  AB Science SA951
  AbbVie Inc.961
  Ablynx NV971
  Acorda Therapeutics, Inc.981
  Actelion Ltd991
  Addex Therapeutics Ltd1001
  Adhaere Pharmaceuticals, Inc.1011
  Aegis Therapeutics, LLC1021
  Affectis Pharmaceuticals AG1031
  AiCuris GmbH &Co. KG1041
  Alkermes Plc1051
  Alpha Cancer Technologies Inc.1061
  Amarna Therapeutics B.V.1071
  Anavex Life Sciences Corp.1081
  Antisense Therapeutics Limited1091
  Antitope Limited1101
  Aphios Corporation1111
  Apitope International NV1121
  Arena Pharmaceuticals, Inc.1131
  Argos Therapeutics, Inc.1141
  Arrien Pharmaceuticals, LLC1151
  Artielle ImmunoTherapeutics, Inc.1161
  Astellas Pharma Inc.1171
  Asterias Biotherapeutics, Inc.1181
  Atara Biotherapeutics, Inc.1191
  Athersys, Inc.1201
  Axxam SpA1211
  Baliopharm AG1221
  Bio-Cancer Treatment International Limited1231
  BioAegis Therapeutics, Inc.1241
  BIOCAD1251
  Biocon Limited1261
  Biogen, Inc.1271
  Biogenomics Limited1281
  Biokine Therapeutics Ltd.1291
  Biomar Microbial Technologies1301
  Bionature E.A. Ltd.1311
  Bioncotech Therapeutics S.L.1321
  Bionovis SA1331
  Bionure Farma, S.L.1341
  Biovista Inc.1351
  Bird Rock Bio, Inc.1361
  Bolder Biotechnology, Inc.1371
  BrainStorm Cell Therapeutics Inc.1381
  C4X Discovery Holdings PLC1391
  Caladrius Biosciences, Inc.1401
  CASI Pharmaceuticals Inc.1411
  Catalyst Pharmaceuticals, Inc.1421
  Celgene Corporation1431
  Cell Cure Neurosciences, Ltd.1441
  Cell2B S.A.1451
  Cellceutix Corporation1461
  Chong Kun Dang Pharmaceutical Corp.1471
  Cognosci, Inc.1481
  Coherus BioSciences, Inc.1491
  Commence Bio, Inc.1501
  Compugen Ltd.1511
  Connexios Life Sciences Pvt. Ltd.1521
  Critical Outcome Technologies Inc.1531
  CuraVac, Inc.1541
  Cyxone AB1551
  Dimerix Bioscience Pty Ltd1561
  Eisai Co., Ltd.1571
  Endece, LLC1581
  Euroscreen S.A.1591
  Evgen Pharma Plc1601
  Evotec AG1611
  F. Hoffmann-La Roche Ltd.1621
  Flex Pharma, Inc.1631
  Forward Pharma A/S1641
  FPRT Bio Inc.1651
  Gemac1661
  Genervon Biopharmaceuticals, LLC1671
  GeNeuro SA1681
  Genzyme Corporation1691
  GlaxoSmithKline Plc1701
  Glialogix, Inc.1711
  Hansa Medical AB1721
  Hanwha Chemical Corporation1731
  Harbor Therapeutics, Inc.1741
  HitGen LTD1751
  Hutchison MediPharma Limited1761
  Iltoo Pharma1771
  Immune Response BioPharma, Inc.1781
  ImmuNext, Inc.1791
  Immungenetics AG1801
  InDex Pharmaceuticals AB1811
  Innate Immunotherapeutics Ltd1821
  Inovio Pharmaceuticals, Inc.1831
  Io Therapeutics, Inc.1841
  Jyant Technologies, Inc.1851
  Kadimastem Ltd.1861
  Kadmon Corporation, LLC1871
  KAHR medical Ltd.1881
  KaloBios Pharmaceuticals, Inc.1891
  Kareus Therapeutics, SA1901
  Karo Pharma AB1911
  Karyopharm Therapeutics, Inc.1921
  Kezar Life Sciences, Inc.1931
  Kineta, Inc.1941
  Kyorin Pharmaceutical Co., Ltd.1951
  Lead Discovery Center GmbH1961
  LFB S.A.1971
  Lipocure Ltd.1981
  MacroGenics, Inc.1991
  MAKScientific, LLC2001
  Mallinckrodt Plc2011
  Mapi Pharma Ltd.2021
  Marathon Pharmaceuticals, LLC2031
  MedAnnex Ltd2041
  MedDay SA2051
  Medestea Research &Production S.p.A.2061
  MedImmune, LLC2071
  Meiji Seika Pharma Co., Ltd.2081
  Merck KGaA2091
  Meta-IQ ApS2101
  Mitochon Pharmaceuticals, Inc.2111
  Mitsubishi Tanabe Pharma Corporation2121
  MorphoSys AG2131
  Neuralstem, Inc.2141
  Neuren Pharmaceuticals Limited2151
  Neurotec Pharma SL2161
  New World Laboratories, Inc.2171
  Novartis AG2181
  NovImmune SA2191
  Nuevolution AB2201
  Octapharma AG2211
  Omeros Corporation2221
  OncoImmune, Inc.2231
  Opexa Therapeutics, Inc.2241
  OPKO Health, Inc.2251
  OSE Immunotherapeutics2261
  Parvus Therapeutics, Inc.2271
  Peptinov SAS2281
  Pfenex Inc.2291
  Pfizer Inc.2301
  PharmaEssentia Corporation2311
  PharmatrophiX, Inc.2321
  Pharmaxis Limited2331
  Pieris Pharmaceuticals, Inc.2341
  Plexxikon Inc.2351
  ProNoxis AB2361
  Prothena Corporation Plc2371
  Q Therapeutics, Inc.2381
  ReceptoPharm, Inc.2391
  RedHill Biopharma Ltd.2401
  RegeneRx Biopharmaceuticals, Inc.2411
  Regenesance BV2421
  Resverlogix Corp.2431
  ReveraGen BioPharma, Inc.2441
  Rigel Pharmaceuticals, Inc.2451
  SanBio, Inc.2461
  Santhera Pharmaceuticals Holding AG2471
  Sareum Holdings Plc2481
  SK Biopharmaceuticals Co., Ltd.2491
  Sorrento Therapeutics, Inc.2501
  Symic Biomedical, Inc.2511
  Synthon Holdings BV2521
  Targazyme, Inc.2531
  Teikoku Pharma USA, Inc.2541
  Teva Pharmaceutical Industries Ltd.2551
  Therapix Biosciences Ltd2561
  TikoMed AB2571
  Toleranzia AB2581
  Topas Therapeutics GmbH2591
  TxCell SA2601
  Vaccinex, Inc.2611
  Vakzine Projekt Management GmbH2621
  Vertex Pharmaceuticals Incorporated2631
  Virogenomics BioDevelopment, Inc.2641
  Vitae Pharmaceuticals, Inc.2651
  VivaCell Biotechnology Espana S.L.2661
  Xenetic Biosciences (UK) Limited2671
  XL-protein GmbH2681
  Yungjin Pharm. Co., Ltd.2691
  Zydus Cadila Healthcare Limited2701
Multiple Sclerosis Therapeutics Assessment27153
  Assessment by Monotherapy Products2711
  Assessment by Combination Products2721
  Assessment by Target27329
  Assessment by Mechanism of Action30218
  Assessment by Route of Administration3202
  Assessment by Molecule Type3222
Drug Profiles324580
  (buspirone + carbidopa + levodopa) Drug Profile3241
  (clarithromycin + clofazimine + rifabutin) Drug Profile3257
  2ME2 Drug Profile3323
  AB-002 Drug Profile3351
  ABS-11 Drug Profile3361
  ABT-555 Drug Profile3371
  ACT-101 Drug Profile3382
  ADX-88178 Drug Profile3402
  AFC-5128 Drug Profile3421
  AGS-010 Drug Profile3432
  AIC-284 Drug Profile3451
  AKP-11 Drug Profile3462
  aldesleukin Drug Profile3481
  ALKS-8700 Drug Profile3492
  amiselimod hydrochloride Drug Profile3512
  Anatabine Drug Profile3533
  ANAVEX-273 Drug Profile3568
  Annexuzlimab Drug Profile3641
  ANT-1034 Drug Profile3651
  APD-334 Drug Profile3662
  APH-1305 Drug Profile3681
  APH-1403 Drug Profile3691
  ARN-6039 Drug Profile3701
  ASTOPC-1 Drug Profile3715
  ATL-1102 Drug Profile3765
  ATXMS-2 Drug Profile3811
  ATXMS-3 Drug Profile3821
  AX-007 Drug Profile3831
  AX-024 Drug Profile3841
  AZD-8797 Drug Profile3851
  BA-024 Drug Profile3861
  BBT-032 Drug Profile3871
  BCT-200 Drug Profile3881
  BIIB-061 Drug Profile3891
  biotin Drug Profile3904
  BKT-130 Drug Profile3941
  BN-201 Drug Profile3952
  BNV-004 Drug Profile3971
  BNZ-1321 Drug Profile3981
  BVA-101 Drug Profile3991
  CAR-208 Drug Profile4001
  CBP-307 Drug Profile4011
  CD-24Fc Drug Profile4022
  Cellular Immunotherapy for Central Nervous System Disorders Drug Profile4041
  Cellular Immunotherapy for Multiple Sclerosis Drug Profile4051

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Multiple Sclerosis - Pipeline Review, H1 2016" Jun 15, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Multiple-Sclerosis-Pipeline-Review-H1-2016-2088-15935>
  
APA:
Global Markets Direct - Market Research. (2016). Multiple Sclerosis - Pipeline Review, H1 2016 Jun 15, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Multiple-Sclerosis-Pipeline-Review-H1-2016-2088-15935>
  
US$ 2,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.